Menu

BONESUPPORT has eight ongoing share related incentive programs: three employee stock option programs, four performance share programs and one warrant program.

Employee stock options programs

Of the three employee stock option programs, two run over ten years and expire 2022 and 2025 and one program runs over eight years and expires 2024. Each stock option gives the holder the right to acquire 0.2 ordinary shares when exercising the option. The employee stock options are vested according to a schedule in each program. A condition for allotment of options is employment or a contractual relationship with BONESUPPORT at each vesting date. Of the allocated 25.7 million options, 21.5 million options were fully vested before September 30, 2020.

Performance share programs

There are three programs for newly recruited employees and one program for three directors. All programs run over four years; the one that is aimed for the directors runs until 2021, the other programs runs until 2021, 2022 and 2023 respectively. Each savings share gives the opportunity to be allotted a maximum of 2,3 or 4 performance shares without payment depending on share price development and BONESUPPORT’s development in terms of sales and EBITDA during the duration of the program. The performance shares are issued in the form of class C-shares with a subscription price and quota value of SEK 0.625 per share.

Employee stock options and performance shares are valued at fair value at the date of allocation. The total cost is distributed over the vesting period. The cost is accounted for as personnel cost and is credited to equity. The social security cost is revalued at fair value. When the options are exercised, BONESUPPORT issues new shares. Payments received on behalf of the shares issued are credited to equity.

Warrant programs

There is one warrant program. It was executed in 2018 and gives the holder the right to acquire 1 share per warrant.

Further information on these programs is presented in Notes 12 and 23 in the Annual Report for 2019.

Employee stock option programs

No of options[1]

Equal to no of shares

WAEP[2]

Balance January 1, 2020

4,977,020

995,404

12.12

Exercised

-3,097,041

-619,407

22.57

Returned

-194,167

-38,833

26.50

Balance September 30, 2020

1,685,812

337,164

11.29

       

Performance share programs

 

 

Right to no of shares

Balance January 1, 2020

   

1,225,000

Returned

   

-80,000

Balance September 30, 2020

   

1,145,000

 

 

 

 

Warrant programs

No of warrants

Equal to no of shares

WAEP[2]

Balance January, 2020

4,606,664

1,210,210

20.87

Exercised

-4,245,568

-849,114

26.50

Balance September 30, 2020

361,096

361,096

15.94



[1] Not allocated options amounted to 4,119,547 as at September 30, 2020.

[2] Weighted Average Exercise Price per share (SEK).

 

Emil Billbäck has more than 20 years’ experience in commercial operations within the life science industry - 11 years of which gained in senior leadership positions under private equity ownership (Montagu and EQT). Most recently, he was Senior Advisor to the recently merged BSN medical/ SCA entity. Before the merger he was Executive Vice President EMEA and Head of Global Commercial Operations, at BSN medical. Prior to this Emil held several roles at BSN medical as Interim President North America, Group Director Commercial Operations, Group Director R&D and President APAC. Before joining BSN medical, Emil worked at Beiersdorf and AstraZeneca. While Swedish native, Emil has lived and worked 4 years in the US and more than 9 years in Germany. He holds a BSc in Business Administration from Karlstad University.

pdf EMIL BILLBÄCK

Håkan Johansson började på BONESUPPORT som Chief Financial Officer i november 2018. Han har mer än 20 års erfarenhet som CFO och andra seniora management roller från flera branscher inom offentliga och privata sektorn. Dessförinnan BONESUPPORT var Håkan Johansson CFO för Northern Europe på Thunstall Healthcare Group (2012–18), ett globalt företag inom trygghetsteknik och systemlösningar för vård och omsorg. Tidigare har han arbetat på leksakstillverkaren BRIO AB (publ) och Arctic Paper Group. Håkan Johansson har en examen som Civilekonom från Mittuniversitetet.

pdf HÅKAN JOHANSSON

Kristina Ingvar has overall responsibility for global quality and regulatory compliance at BONESUPPORT. She joined as Executive Vice President Quality Management & Regulatory Affairs in February 2020, bringing more than 20 years of life science experience from areas across the value chain, in both large and small companies. Prior to joining BONESUPPORT, Kristina spent almost 13 years with Novo Nordisk, most recently in a role as Global Program Vice President, Global Regulatory Affairs. She has held various other product-, project- and people management positions in the regulatory, quality, safety and medical areas. She holds a Bachelor of Medicine and a Diploma in Marketing Management, with additional studies in Public Health.

pdf KRISTINA INGVAR

Dr Diefenbeck rekryterades till BONESUPPORT i april 2017. Under 2014 grundade han Scientific Consulting in Orthopaedic Surgery och har tidigare arbetat med BONESUPPORT i ett antal projekt som oberoende klinisk rådgivare. Han är för närvarande hederskonsult hos Nuffield Orthopaedic Centre vid Universitetssjukhuset i Oxford. Dr Diefenbeck studerade medicin i München och utbildade sig till ortopedikirurg med specialisering inom traumavård och beninfektioner. Han har 14 års klinisk erfarenhet från olika sjukhus i Tyskland (BG Unfallklinik Murnau, BG Kliniken Bergmannstrost Halle/Saale, Universitetssjukhuset Jena och Schön Klinik Hamburg Eilbek). Han doktorerade 2011 vid Universitetssjukhuset Jena och har sedan dess varit involverad i kirurgiundervisning och utbildningsprogram för studenter. Han är författare till 24 publicerade forskningsartiklar inom området.

pdf MICHAEL DIEFENBECK

Fergus MacLeod joined BONESUPPORT as General Manager & Executive Vice President responsible for Commercial Operations across EUROW in November 2019. Fergus has a proven track record in senior, international medical device leadership roles in a career spanning over 20 years. Most recently, Fergus has held General Management responsibility for the Global Medical Device assets at Johnson Matthey, a publicly traded British company and previously as Vice President & Managing Director with responsibility for Commercial Operations across EMEA for RTI Surgical, an international Medical Device and Orthobiologics company and over eight years at Stryker in roles of increasing responsibility. Fergus over his career has acquired extensive experience in building and leading high performing teams and commercializing medical technologies. Fergus has recently completed an Executive Leadership program at the Center for Creative Leadership and holds a HND in Business & Finance from the University of Bedfordshire.

pdf FERGUS MACLEOD

Michael Roth joined BONESUPPORT as the General Manager and Executive Vice President Commercial Operations for North America in June 2020. Michael has over 25 years of direct and distributor-based sales, marketing and sales leadership experience within the orthopaedic market sector for both large and small companies. Most recently, he was Vice President of Sales and Marketing for Surgical Planning Associates (HipXpert) where he led the strategic initiative to refine the marketing strategy, increase commercial brand visibility and grow sales. He also held Vice President of Sales positions in the east region with both Wright Medical and Microport Orthopaedics where he had a sustained track record of building strong sales networks, developing dynamic management teams and cultivating a high-performance sales culture in the competitive large joint, foot and ankle and orthobiologic market segments. Mr. Roth holds a bachelor degree in International Development from Clark University.

pdf MIKE ROTH

Helena L Brandt is a senior HR leader with more than 20 years’ experience gained from a broad range of industries. Ms Brandt has held global HR leadership roles at Astra Zeneca, Sony and Tetra Pak, developing organizational leadership and teams. She holds an International Business & Economics Master’s Degree from Lund University, Sweden, and also studied at the University of Cologne in Germany and at the universities of Cincinnati and Delaware in the U.S.

pdf HELENA BRANDT

Annelie Aava Vikner började på BONESUPPORT som Executive Vice President (EVP) Marketing & Communications i mars 2019. Hon har mer än 20 års erfarenhet inom medicinteknik och läkemedel. Innan hon började på BONESUPPORT var hon verksam i flertalet ledande regionala marknadsföringstjänster, inom Medtronic, ett av världens ledande medicintekniska företag (2002-2019). Hennes senaste roll innan BONESUPPORT var som Senior Strategy & Marketing Manager, RTG, ABGI&NORDICS (Restorative Therapy Group, Österrike, Schweiz, Benelux, Grekland, Israel och Norden). Aava Vikner har en kandidatexamen i kemi från Linköpings universitet samt en vidareutbildning inom ledarskap från Glasgow Caledonian University.

pdf ANNELIE AAVA VIKNER

Johan Olsson ansvarar för leveranskedjan och har en civilingenjörsexamen i maskinteknik (1991) från Lunds universitet. Han kom till BONESUPPORT 2007 som produktions- och logistikchef och dessförinnan arbetade han hos Gambro som chef för intensivvårdslinjen (2000–2007), där han bland annat ansvarade för överflyttningen av Gambros produktion från Italien till Sverige. Dessförinnan hade Johan flera olika ledande befattningar inom logistik, inköp och tillverkning hos olika konsumentproduktföretag.

pdf JOHAN OLSSON